Changes in Inflammatory and Atherogenesis Biomarkers With the 2-Drug Regimen Dolutegravir Plus Lamivudine in Antiretroviral Therapy–Experienced, Virologically Suppressed People With HIV-1: A Systematic Literature Review
| dc.contributor.author | Llibre, Josep M | es |
| dc.contributor.author | Cahn, Pedro | es |
| dc.contributor.author | Lo, Janet | es |
| dc.contributor.author | Barber, Tristan | es |
| dc.contributor.author | Mussini, Cristina | es |
| dc.contributor.author | van Welzen, Berend J | es |
| dc.contributor.author | Hernandez, Beatriz | es |
| dc.contributor.author | Donovan, Cynthia | es |
| dc.contributor.author | Kisare, Michelle | es |
| dc.contributor.author | Sithamparanathan, Myooran | es |
| dc.date.accessioned | 2024-04-10T17:05:01Z | |
| dc.date.available | 2024-04-10T17:05:01Z | |
| dc.date.issued | 2022-02-10 | |
| dc.description | [ABSTRACT]. Background. The 2-drug regimen dolutegravir plus lamivudine has demonstrated long-term noninferior efficacy vs 3-/4-drug regimens (3/4DRs) in phase 3 trials. This systematic literature review summarizes clinical trial and real-world evidence evaluating impact of dolutegravir plus lamivudine on inflammatory and atherogenesis biomarkers in people with human immunodeficiency virus type 1 (PWH). Methods. Using Ovid MEDLINE, Embase, PubMed, and Cochrane library databases and conference proceedings, we searched for studies published from 1 January 2013 to 14 July 2021, reporting changes in inflammatory and atherogenesis biomarkers with dolutegravir plus lamivudine in antiretroviral therapy–experienced, virologically suppressed PWH aged ≥18 years. Results. Four records representing 2 randomized controlled trials (RCTs) and 6 records of real-world evidence met eligibility criteria. All real-world studies evaluated CD4+/CD8+ ratio, while only 1 assessed inflammatory biomarkers. Across both RCTs, no consistent pattern of change in biomarkers was observed between dolutegravir/lamivudine and 3/4DR comparators. There were significant changes in soluble CD14 favoring dolutegravir/lamivudine in TANGO at weeks 48 and 144 and SALSA at week 48, and in interleukin-6 favoring the control group in TANGO at weeks 48 and 144. In the real-world study evaluating inflammatory bio- markers, median soluble CD14 significantly decreased 48 weeks postswitch to dolutegravir plus lamivudine (P < .001), while other biomarkers remained stable. In all 6 real-world studies, increases in CD4+/CD8+ ratio were reported after switch to dolutegravir plus lamivudine (follow-up, 12–60 months). Conclusions. Results show that dolutegravir plus lamivudine has a comparable impact on inflammatory and atherogenesis bio- markers vs 3/4DRs, with no consistent pattern of change after switch in virologically suppressed PWH. | es_ES |
| dc.identifier.doi | https://doi.org/10.1093/ofid/ofac068 | es |
| dc.identifier.doi | https://doi.org/10.1093/ofid/ofac068 | es |
| dc.identifier.uri | https://repositorio.huesped.org.ar/handle/123456789/3934 | |
| dc.language | en | es_ES |
| dc.rights | Creative Commons 4.0 | es |
| dc.rights.uri | https://creativecommons.org/ licenses/by-nc-nd/4.0/ | es |
| dc.source | Open Forum Infectious Diseases;9(4)2022:ofac068. eCollection 2022 Apr. | |
| dc.subject | VIH-1 | es_ES |
| dc.subject | Biomarcadores | es_ES |
| dc.subject | Aterosclerosis | es_ES |
| dc.subject | Lamivudine | es_ES |
| dc.subject | Revisión | es_ES |
| dc.title | Changes in Inflammatory and Atherogenesis Biomarkers With the 2-Drug Regimen Dolutegravir Plus Lamivudine in Antiretroviral Therapy–Experienced, Virologically Suppressed People With HIV-1: A Systematic Literature Review | es_ES |